Janus Henderson Group PLC Grows Position in Relmada Therapeutics, Inc. $RLMD

Janus Henderson Group PLC lifted its holdings in Relmada Therapeutics, Inc. (NASDAQ:RLMD) by 52.2% in the first quarter, HoldingsChannel reports. The firm owned 11,063,862 shares of the company’s stock after purchasing an additional 3,793,862 shares during the quarter. Janus Henderson Group PLC owned 0.11% of Relmada Therapeutics worth $76,892,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in Relmada Therapeutics in the second quarter worth $28,000. LMR Partners LLP purchased a new position in shares of Relmada Therapeutics during the second quarter worth approximately $33,000. Goldman Sachs Group Inc. purchased a new stake in shares of Relmada Therapeutics in the 1st quarter worth $33,000. Schonfeld Strategic Advisors LLC purchased a new stake in Relmada Therapeutics in the fourth quarter worth about $64,000. Finally, Jane Street Group LLC purchased a new stake in shares of Relmada Therapeutics in the 2nd quarter worth approximately $69,000. 45.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Thursday, June 18th. HC Wainwright started coverage on Relmada Therapeutics in a research report on Thursday, June 18th. They set a “buy” rating and a $12.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Relmada Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

Relmada Therapeutics Stock Performance

Shares of RLMD stock opened at $5.31 on Friday. The firm has a market capitalization of $556.97 million, a P/E ratio of -4.87 and a beta of 0.41. Relmada Therapeutics, Inc. has a fifty-two week low of $0.55 and a fifty-two week high of $8.00. The stock’s fifty day moving average is $6.24 and its two-hundred day moving average is $5.89.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, equities analysts forecast that Relmada Therapeutics, Inc. will post -0.82 earnings per share for the current year.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.